drugset / Trial / NCT04901806
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.
Timeline
- Start
- 2021-07-20
- Primary completion
- 2023-07-26
- Completion
- 2023-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PALTIMATRECTINIB | Small molecule | — | Oral |